New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
05:50 EDTTWX, VRXStocks with implied volatility movement; TWX VRX
Stocks with implied volatility movement; Time Warner (TWX) 30, Valeant (VRX) 49 according to iVolatility.
News For TWX;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 16, 2014
06:31 EDTTWXTime Warner upgraded to Buy from Neutral at BofA/Merrill
October 15, 2014
13:22 EDTTWXEarnings Preview: Netflix falls after HBO announced plans of streaming service
Netflix (NFLX) is expected to report third quarter earnings after the market close on Wednesday, October 15 with a conference call scheduled for 6:00 pm ET. Netflix is an Internet subscription service that allows members to watch TV shows and movies through DVD and on-demand streaming. EXPECTATIONS: Analysts are looking for earnings per share of 93c on revenue of $1.41B. The consensus range is 86c-$1.24 for EPS, and $1.39B-$1.43B for revenue, according to First Call. LAST QUARTER: Netflix reported second quarter EPS of $1.15 against estimates of $1.16, on revenue of $1.15B against estimates of $1.33B. It reported Q2 total streaming net additions of 1.69M and Q2-end total streaming members of 50.05M. The company reports Q2 international streaming net additions of 1.12M and Q2-end members of 13.8M. Netflix gave Q3 EPS guidance of 89c and revenue guidance of $1.22B. It also expects to add 3.69M net additions, with international approaching contribution profitability. Netflix said it can achieve U.S.-like margins in its international business. During its Q2 earnings interview, Netflix said it sees a dip in free cash flow for the fourth quarter of 2014 and the first quarter of 2015 as company expands original content. NEWS: Netflix launched in several countries in the past quarter, including France, Germany, Gelgium Austria, Switzerland, and Luxemburg. It also signed a deal with Weinstein Co. to release a feature film sequel to "Crouching Tiger Hidden Dragon" that will be released to a number of IMAX (IMAX) theaters. Netflix signed Judd Apatow to a two-year commitment for an original comedy series, and Adam Sandler to star in four feature films. The company announced a peering deal with Time Warner Cable (TWC) for faster streams and direct access. In a recent post on Facebook, CEO Reed Hastings said the company passed Time Warner's HBO in subscriber revenue. HBO, however, announced plans today to launch a standalone streaming service in the U.S. that does not require a cable TV subscription. STREET RESEARCH: MKM Partners said Netflix's international opportunity is larger than most realize and will eventually be able to provide a global product. The company's price target was raised at RBC Capital due to the opportunities in new European markets, along with favorable survey results in the U.S. and the U.K. Barclays and BTIG upgraded the company, saying international estimates are likely achievable no longer see the stock as underperforming its peers. BTIG expects Netflix's streaming service may reach 100M subscribers worldwide by 2017. Ahead of Q3 earnings, Canaccord said Netflix will likely report in-line results with continued strong subscriber additions and improved international performance. PRICE ACTION: Netflix shares have fell more than to 3.31% since the first day of trading following the company's Q2 report. In Wednesday mid-day trading ahead of Q3 report, Netflix shares are trading down 2.67%.
13:07 EDTVRXAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
12:36 EDTTWXOn The Fly: Midday Wrap
Subscribe for More Information
12:26 EDTTWXNetflix obtains streaming licensing rights to 'Friends'
Subscribe for More Information
10:55 EDTTWXHBO to launch standalone online service in 2015
HBO's plans to launch a stand alone streaming service in the U.S. that does not require a cable TV subscription were announced at Time Warner's (TWX) analyst day meeting. HBO's upcoming service may be viewed as another competitor to Netflix (NFLX).
10:03 EDTTWXTime Warner's Turner unit sees low double-digit operating income CAGR 2013-18
Subscribe for More Information
09:59 EDTTWXTime Warner CEO says has more than sufficient scale, sees doubling EPS
Subscribe for More Information
09:52 EDTTWXTime Warner CEO sees investing more in content over time
Time Warner notes it invested $13.8B in content in 2013. Time Warner CEO Jeff Bewkes is speaking at the company's investor day meeting.
09:51 EDTTWXTime Warner sees adjusted EPS $6 by 2016, $8 by 2018
Subscribe for More Information
October 10, 2014
07:37 EDTVRXActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:16 EDTVRXAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
07:04 EDTTWXAmazon in talks to join digital locker for movies. WSJ reports
Subscribe for More Information
06:42 EDTTWXTime Warner CEO to be questioned on growth plans, NY Post reports
Subscribe for More Information
05:18 EDTTWXTime Warner to host investor meeting
Investor meeting to be held on October 15 at 9:30 am. Webcast Link
October 9, 2014
14:21 EDTVRXAllergan in good position to be patient given raised outlook, says BMO Capital
After speaking with Allergan's (AGN) CEO and CFO, BMO Capital believes the company is increasing its intrinsic value with its raised earnings guidance and that it is in a good position to be patient given that Valeant (VRX) most recent bid represents an 8% discount to Allergan's current share price. BMO said it is reviewing its forecasts for Allergan after the guidance increase, noting that it previously valued Allergan at $230 per share on a standalone basis. The firm maintains its Outperform rating on the stock.
12:28 EDTVRXAllergan price target raised to $230 from $210 at BTIG
BTIG said it expected Allergan to beat the consensus forecast for Q3 EPS, but not by as much as it did, and the firm did not expect the company to raise its future EPS outlook yet again. BTIG feels the stock's move higher indicates Valeant (VRX) or Actavis (ACT) would need to bid above $200 if they hope to buy the company. BTIG maintains its Buy rating on Allergan and raised its price target on the stock to $230 from $210.
11:14 EDTVRXAllergan raises outlook again as Valeant pursuit continues
Drug maker Allergan (AGN) this morning preannounced stronger than expected results and again raised its fiscal year profit guidance. The beat and raise results come after The Wall Street Journal reported on Tuesday that drug maker Valeant (VRX) and hedge fund Pershing Square intend to raise their previous bid for Allergan by $15 per share to about $191. Meanwhile, also on Tuesday, Reuters said that drug maker Actavis (ACT) plans to make a new merger offer to Allergan, and sources indicated to the news service that Allergan may be willing to consider an offer from Actavis if the bid is for more than $200 per share. WHAT'S NEW: Allergan estimated that its third quarter earnings per share would come in at $1.76-$1.78, versus analysts' consensus estimate of $1.48. The drug maker had previously provided Q3 EPS guidance of $1.44-$1.47. Allergan raised its fiscal 2014 EPS guidance to $6.20-$6.25 from $5.74-$5.80. Analysts' consensus estimate was $5.81. This is the fourth time that Allergan has raised its guidance this year. Allergan said that its markets have been strong around the world, while it is gaining market share in most categories. ANALYST REACTION: In a note to investors today, Wells Fargo analyst Larry Biegelsen wrote that, in the wake of Allergan's guidance increase, the company's price to earnings multiple could expand to 22x its estimated 2016 earnings, up from its current multiple of 19x. In addition to the raised guidance, a potential accretive acquisition by Allergan and the possibility that it will be acquired make such an increase in the multiple "quite possible," Biegelsen contended. He kept an Outperform rating on the stock. WHAT'S NOTABLE: Allergan has reportedly held advanced talks about acquiring another company in the sector, Salix (SLXP), although CNBC's David Faber on October 2 reported that the talks between the two companies about a merger had "cooled considerably." PRICE ACTION: In late morning trading, Allergan rose fractionally to $191.06 while Valeant slid 1.5% to $124.08.
08:50 EDTVRXAllergan shares have further upside, says Wells Fargo
Subscribe for More Information
October 8, 2014
06:23 EDTVRXActavis more inclined to pursue Allergan over Salix, says Citigroup
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use